Search Results
24 protocol(s) meet the specified criteria
100288Open  
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: Phase III Prospective Randomized Trial

103657Open  
Exploratory Phase IB Study to Assess the Effects of Merestinib on Bone Metastases in Subjects with Breast Cancer

103976Open  
Phase II Trial of a 9-Day Course of Whole Breast Radiotherapy for Early Stage Breast Cancer

104258Open  
Phase I/II, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

104630Open  
Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Positive Solid Tumors (FIM)

105517Open  
Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery

105539Open  
Phase II Randomized, Double-Blinded, Controlled Study of Tucatinib versus Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)

105691Open  
Nonpharmacologic Interventions for Fatigue in Patients with Cancer

107224Open  
Randomized Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

109583Open  
Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

109587Open  
Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) either Alone or in Combination with Anti-PD-L1 Therapy in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)

114785Open  
Tailor RT: Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

115800Not Open *
Phase I/II Multicenter, Open-Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women with Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2 Negative Breast Cancer

117145Not Open *
Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

69515Open  
Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment

76139Open  
Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy

76853Open  
Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

77671Open  
Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes after Neoadjuvant Chemotherapy

81405Not Open *
Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

94979Open  
Study to Identify Predictors of Response to Duloxetine in Breast Cancer Patients with Chronic Pain

95175Open  
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL)

99137Open  
Randomized Phase III Double-Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: ABC Trial

99894Open  
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib plus Anti-HER2 Therapy plus Endocrine Therapy versus Anti-HER2 Therapy plus Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

99906Open  
Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors